Focuses on developing therapies for kidney diseases and related disorders.
XORTX Therapeutics Inc., a bio-pharmaceutical firm headquartered in Vancouver, Canada, specializes in the development and commercialization of innovative therapies targeting progressive kidney diseases, diabetes, insulin resistance, and metabolic syndrome. The company's diverse pipeline includes XRx-008, an advanced-stage therapy designed to address autosomal dominant polycystic kidney disease (ADPKD), a genetic disorder leading to cyst formation in the kidneys. Additionally, XORTX is advancing XRx-101, an agent aimed at lowering uric acid levels, which shows promise in managing COVID-19 infections and preventing associated acute kidney injuries.
In its commitment to addressing diabetic nephropathy, XORTX Therapeutics is actively developing XRx-221, a series of xanthine oxidase inhibitors intended to mitigate kidney complications stemming from diabetes. Collaborating closely with the renowned Icahn School of Medicine, the company conducts studies focused on understanding acute kidney injury and hyperuricemia prevalence among COVID-19 patients, underscoring its dedication to advancing treatments for critical health challenges.
Founded on a mission to pioneer therapeutic solutions for complex renal and metabolic disorders, XORTX Therapeutics combines rigorous research and strategic partnerships to drive medical innovation. With a robust pipeline and a focus on addressing unmet medical needs, the company aims to improve outcomes and quality of life for patients worldwide facing these challenging conditions.